- Clinical-stage biopharma NextCure ( NASDAQ: NXTC ) and South Korea-based LegoChem Biosciences on Tuesday said they would collaborate on developing a cancer antibody drug conjugate.
- The antibody drug conjugate would target the B7-H4 gene, and would use NXTC's antibody and LegoChem's technology.
- The deal also has options for the companies to nominate two additional targets for antibody drug conjugate development beyond B7-H4.
- "Under the terms of the agreement, both parties will equally share the costs to develop the molecules and profits on commercialized products," the companies said in a statement .
- NXTC stock earlier closed -1.8% at $1.66.
For further details see:
NextCure, South Korea's LegoChem Biosciences to develop antibody drug conjugates